TY - JOUR
T1 - Cefodizime in complicated urinary tract infections
AU - Tsugawa, Masaya
AU - Yamada, Daisuke
AU - Nasu, Yoshitsugu
AU - Kishi, Mikio
AU - Mizuno, Akihiro
AU - Kumon, Hiromi
AU - Ohmori, Hiroyuki
AU - Nanba, Katsuichi
AU - Katayama, Yasuhiro
AU - Kondo, Katsuyoshi
AU - Akaeda, Teruaki
AU - Takamoto, Hitoshi
PY - 1988/1/1
Y1 - 1988/1/1
N2 - We studied the antibacterial activity and clinical efficacy of cefodizime, a new cephem antibiotic. 1. The antibacterial activity of cefodizime was weak against P. aeruginosa, but excellent against E. coli, K. pnessmoniae, P. mirabilis and S. marcescens. Against E. faecalis and S. marcescens the drug was superior to CPZ and LMOX, but against P. aeruginosa it was inferior to CTX, CPZ and LMOX. 2. Thirty-one patients with complicated urinary tract infection were treated with cefodizime. According to the criteria of the UTI Committee, the overall clinical efficacy rate was 70.4%(19/27). 3. As for side-effects, diarrhea was observed in 1 patient (3%), and abnormal laboratory findings were observed in 3 patients, showing transient elevation of GOT/GPT or anemia.
AB - We studied the antibacterial activity and clinical efficacy of cefodizime, a new cephem antibiotic. 1. The antibacterial activity of cefodizime was weak against P. aeruginosa, but excellent against E. coli, K. pnessmoniae, P. mirabilis and S. marcescens. Against E. faecalis and S. marcescens the drug was superior to CPZ and LMOX, but against P. aeruginosa it was inferior to CTX, CPZ and LMOX. 2. Thirty-one patients with complicated urinary tract infection were treated with cefodizime. According to the criteria of the UTI Committee, the overall clinical efficacy rate was 70.4%(19/27). 3. As for side-effects, diarrhea was observed in 1 patient (3%), and abnormal laboratory findings were observed in 3 patients, showing transient elevation of GOT/GPT or anemia.
UR - http://www.scopus.com/inward/record.url?scp=0023696995&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023696995&partnerID=8YFLogxK
U2 - 10.11250/chemotherapy1953.36.Supplement5_677
DO - 10.11250/chemotherapy1953.36.Supplement5_677
M3 - Article
AN - SCOPUS:0023696995
VL - 36
SP - 677
EP - 690
JO - Chemotherapy
JF - Chemotherapy
SN - 0009-3165
ER -